AIG
ELVN icon

American International Group’s Enliven Therapeutics ELVN Stock Holding History

American International Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,503
Closed -$202K – 843
2024
Q1 		$202K Sell
11,503
-100
-0.9% -$1.53K ﹤0.01% 2145
2023
Q4 		$161K Sell
11,603
-46
-0.4% -$563 ﹤0.01% 2289
2023
Q3 		$159K Buy
11,649
+414
+4% +$6.97K ﹤0.01% 2247
2023
Q2 		$229K Buy
+11,235
New +$227K ﹤0.01% 2088
2021
Q2 		– Sell
-1,116
Closed -$38 – 3161
2021
Q1 		$38 Buy
1,116
+3
+0.3% +$152 ﹤0.01% 3041
2020
Q4 		$98 Buy
1,113
+374
+51% +$31.4K ﹤0.01% 2670
2020
Q3 		$60K Sell
739
-17
-2% -$1.53K ﹤0.01% 2808
2020
Q2 		$84K Buy
+756
New +$84.6K ﹤0.01% 2630

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American International Group's ELVN Position: Q2 2024 in Review

American International Group sold out of Enliven Therapeutics (ELVN) in Q2 2024, closing a stake of 11,503 shares — an estimated $202K sold.

American International Group first reported a position in ELVN in Q2 2020 and held it in 8 quarters. The position peaked at $229K in Q2 2023. 93 funds tracked by Wall St. Rank hold ELVN as of Q2 2024.

  • American International Group reported no remaining Enliven Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 11,503 Enliven Therapeutics shares in Q2 2024, an estimated $202K.
  • American International Group first reported a position in Enliven Therapeutics in Q2 2020 and held it in 8 quarters.
  • American International Group's Enliven Therapeutics position peaked at $229K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.